Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study A randomized, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer.

Trial Profile

ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study A randomized, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2018

At a glance

  • Drugs Lapatinib (Primary) ; Docetaxel; Paclitaxel; Trastuzumab
  • Indications Adenocarcinoma; Early breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ALTTO
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 18 Oct 2018 Results assessing the effects of trastuzumab and/or lapatinib on pregnancy outcomes in the NeoALTTO and ALTTO studies (n=92) published in the Cancer
    • 04 Oct 2018 Planned End Date changed from 21 Nov 2022 to 1 Jul 2021.
    • 04 Oct 2018 Planned End Date changed from 21 Nov 2022 to 1 Jul 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top